New and promising DR-TB drugs are grabbing headlines but not reaching patients.
The first new TB drugs in decades have received conditional regulatory approval, but remain largely out of the reach of patients. Re-purposed medicines are showing effectiveness against TB, but aren't registered for that purpose, which hinders their use in treating TB patients.
High prices are another significant barrier to accessing promising new and re-purposed drugs. In this fact sheet, Médecins Sans Frontières (MSF) looks at accessibility of five key drugs: bedaquiline, delamanid, imipenem/cilastatin, clofazimine and linezolid.
Read the issue brief here.
Read MSF's press release here.
Source: Médecins Sans Frontières